Solvonis Therapeutics plc (LON:SVNS)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.2960
+0.0260 (9.63%)
At close: Jan 23, 2026
55.79%
Market Cap20.15M
Revenue (ttm)n/a
Net Income (ttm)-2.59M
Shares Out6.81B
EPS (ttm)-0.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume29,726,460
Average Volume34,187,910
Open0.2700
Previous Close0.2700
Day's Range0.2600 - 0.2960
52-Week Range0.1095 - 0.4000
Beta1.57
RSI55.34
Earnings DateApr 15, 2026

About Solvonis Therapeutics

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product candidate includes SVN-SDN-14 for the treatment of post-traumatic stress disorder. The company was formerly known as Graft Polymer... [Read more]

Founded 2017
Employees 3
Stock Exchange London Stock Exchange
Ticker Symbol SVNS
Full Company Profile

Financial Performance

Financial Statements